Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A4YK
|
|||
| Former ID |
DNCL002209
|
|||
| Drug Name |
PBI-05204
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [2] | ||
| Company |
Phoenix Biotechnology
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H48O9
|
|||
| Canonical SMILES |
CC1C(C(CC(O1)OC2CCC3(C(C2)CCC4C3CCC5(C4(CC(C5C6=CC(=O)OC6)OC(=O)C)O)C)C)OC)O
|
|||
| InChI |
1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1
|
|||
| InChIKey |
JLPDBLFIVFSOCC-XYXFTTADSA-N
|
|||
| CAS Number |
CAS 465-16-7
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:59030
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/potassium-transporting ATPase (SPT ATPase) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02329717) Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health. | |||
| REF 3 | First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf- beta and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec;32(6):1204-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.